Merck spin-off launches first slug of $9.5bn debt-raising
![Pharma_drugs_adobe_575x375.jpg](https://assets.euromoneydigital.com/dims4/default/b01b394/2147483647/strip/true/crop/575x375+0+0/resize/840x548!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2Fe0%2F58%2F8ce0fc2a15cc3f1ce9a75517fd9a%2Fpharma-drugs-adobe-575x375.jpg)
Organon, a spin-off of US pharmaceuticals company Merck, has launched the first $3bn of a $9.5bn capital raising that will give the soon-to-be independent group its own debt capital structure and fund a one-off special dividend to its parent.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: